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Abstract A pregnant young woman with a severe
migraine is prescribed candesartan, an angiotensin II type 1
receptor antagonist (AT II antagonists). This has a positive
effect—except for severe maldevelopment of her fetus.
There is an increase in the use of the fetotoxic drugs, AT II
antagonists and angiotensin-converting enzyme inhibitors,
as prophylactic treatment of migraines, in addition to their
use as hypertensives.
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Introduction
There is an increase in the use of angiotensin II type 1
receptor antagonists (AT II antagonists) and angiotensin-
converting enzyme inhibitors (ACE-inhibitors) as prophy-
lactic treatment of migraines, in addition to their use as
antihypertensives. These drugs pass the placenta and have
highly adverse effects on the renal organogenesis, leading
to maldevelopment firstly of the renal system and sec-
ondarily of the lungs [1, 2].
Case story
A 35-year-old woman has a missed abortion. She is given
hospital treatment. The fetus is autopsied without con-
clusive diagnosis. In the woman’s next pregnancy, only
6 weeks later, an ultrasound examination is conducted in
week 12 and again in week 30. One week later, the
midwife finds a declining symphysis to fundus increment,
and the woman is therefore immediately referred to the
hospital. Anhydramnion is diagnosed. There is severe
pathology of the kidneys and bladder. The development
of the skull, thorax and possibly the intestines are also
pathological. The reasons for the maldevelopment are
unclear.
The woman is healthy, apart from suffering a severe
common migraine. Before pregnancy, she had three to four
attacks every week of unilateral, throbbing pain associated
with nausea, vomiting and photophobia, lasting 6–48 h,
preceded by transient scintillating scotomas. During preg-
nancy, the attacks are milder, shorter and less frequent.
Throughout both pregnancies, she has been taking cande-
sartan (16 mg/day), pramipexole (0.18 mg 39) and ami-
triptyline (25 mg/day) as prophylaxis against migraines, in
addition to zolmitriptan and metoclopramide during
attacks. Candesartan treatment was initiated more than a
year before her first pregnancy by an experienced neurol-
ogist who was also consulted during pregnancy. The
medication was known to her general practitioner and
the doctors who conducted the ultrasound examinations.
The hospital obstetricians documented the medication in
the admission notes in both pregnancies.
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Nonetheless, the fetus is 33 weeks before doctors
become aware that the medication is fetotoxic. Candesar-
tan, an AT II antagonist, is seponated. When the baby is
born, he has renal tubular dysgenesis, hypoplasia of the
skull and the lungs, and hyaline membranes of the lungs.
This is not compatible with life.
Materials and methods
MEDLINE and the Norwegian Database of Adverse
Effects [3] were searched for descriptions of fetal injuries
related to AT II antagonists ACE-inhibitors. Information
about the extent of use of these drugs in Norway was
obtained from the National Prescription Database.
Results
Angiotensin II receptor antagonists and ACE-inhibitors
reduce blood pressure by blocking the renin-angiotensin
system. They also have a positive, prophylactic effect
against migraines, although the mechanisms are poorly
understood. The colocalization of AT1, glutamate and
GABA receptors on medullary rostral ventromedial neu-
rons suggests a nociceptive modulatory [4]. Unfortunately,
these drugs cross the placenta and affect the circulation of
the fetal kidneys, and, more importantly, reduce stimula-
tion of AT II receptors. This has a highly adverse effect on
the renal organogenesis in the second and third trimesters
[5]. The kidneys develop abnormally and are unable to
produce urine; there is oligohydramnion and thereby, inter
alia, maldevelopment of the lungs [1, 2].
The summary of product characteristics in the technical
brochures clearly states that these drugs are fetotoxic and
should not be used during pregnancy [6]. More than 20
cases of fetal injury/maldevelopment after exposure to AT
II antagonists and ACE-inhibitors have been reported in the
literature [1, 2]. Two cases have been reported to the
Norwegian Database of Adverse Effects. Norway has 4.7
million inhabitants.
In Norway, 1.2% of women aged 30–39 years were
dispensed drugs in 2007 that affect the renin-angiotensin
system, an increase compared to 2004. More than 50% of
childbearing women in Norway are more than 30 years old.
The mean age at delivery is increasing and will thus cause
the number of pregnant women with hypertension requiring
medical treatment to increase. In addition, there is reason
to believe that there is an increase in the use of these drugs
against migraines. They are well tolerated, and several
studies have demonstrated their positive prophylactic
effects [7–11]. In American and European guidelines,
candesartan is listed among second- and third-line agents,
respectively, for migraine prophylaxis [12–14]. In Austra-
lia it is not yet listed as an appropriate agent, but is widely
used by the neurologists [15]. This also appears to be the
case in Norway, although it is difficult to document, as
these are not approved drugs against migraines in this
country.
Discussion
Migraine is a most disabling disorder, which can be
extremely difficult to treat. A variety of drugs from diverse
pharmacological classes are in use for migraine prevention.
AT II antagonists and ACE-inhibitors are traditional anti-
hypertensives that have proved to be effective also in
migraine prophylaxis. Their fetotoxic effects have been
demonstrated in humans [1, 2] and well documented in
animal research. When administered to rats, mice or piglets
during renal development these drugs induce severe renal
histological abnormalities, including papillary atrophy,
tubulointerstitial fibrosis and tubular atrophy and dilatation
[16, 17]. Nonetheless, there is reason to believe that an
increasing number of women of reproductive age will use
these drugs. They should be advised of the possible haz-
ards, and treatment should be stopped as soon as pregnancy
is planned or detected.
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